Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

November 11, 2026

Consolidated Financial Results for the Six Months Ended September 30, 2026 (Under Japanese GAAP)

Company name: TOHO HOLDINGS CO., LTD.
Listing: Tokyo Stock Exchange
Securities code: 8129
URL: https://www.tohohd.co.jp/en/
Representative: Hiromi Edahiro / Representative Director, President and CEO
Inquiries: Makoto Kawamura / Senior Executive Corporate Officer and General Manager, Corporate Strategy Division
Telephone: +81-3-6838-2803

Scheduled date to file semi-annual securities report: November 13, 2026
Scheduled date to commence dividend payments: December 1, 2026
Preparation of supplementary material on financial results: Yes
Holding of financial results briefing: Yes (for Institutional Investors and Analysts)

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated financial results for the six months ended September 30, 2026 (from April 1, 2026 to September 30, 2026)

(1) Consolidated operating results (cumulative)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
Six months ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
September 30, 2026	808,544	5.3	4,748	-34.6	6,553	-21.3	4,177	-33.1
September 30, 2025	767,899	1.7	7,258	-1.7	8,329	-3.1	6,244	16.0

Note: Comprehensive income For the six months ended September 30, 2026: ¥4,140 million [-44.1%]
For the six months ended September 30, 2025: ¥7,405 million [-7.8%]

	Basic earnings per share	Diluted earnings per share
Six months ended	Yen	Yen
September 30, 2026	64.10	63.79
September 30, 2025	99.12	92.72

(2) Consolidated financial position

	Total assets	Net assets	Equity-to-asset ratio
As of	Millions of yen	Millions of yen	%
September 30, 2026	786,239	269,505	34.3
March 31, 2026	740,781	271,560	36.6

Reference: Equity As of September 30, 2026: ¥269,314 million
As of March 31, 2026: ¥271,310 million

2. Cash dividends

	Annual dividends per share				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended March 31, 2026	—	45.00	—	120.00	165.00
Fiscal year ending March 31, 2027	—	90.00			
Fiscal year ending March 31, 2027 (Forecast)			—	90.00	180.00

Note: Revision to the forecast of cash dividends most recently announced: None

3. Consolidated financial forecast for fiscal year ending March 31, 2027 (from April 1, 2026 to March 31, 2027)

(Percentages indicate the rate of change compared with the preceding fiscal year.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Net income per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Full year	1,601,000	3.1	14,800	-10.9	16,600	-0.2	12,900	-25.6	197.64

Note: Revision of consolidated financial forecast most recently announced: None

*** Notes**

(1) Significant changes in the scope of consolidation during the period: None
Newly included: –
Excluded: –

(2) Adoption of accounting treatment specific to the preparation of semi-annual consolidated financial statements: None

(3) Changes in accounting policies, changes in accounting estimates, and restatement
(i) Changes in accounting policies due to revisions to accounting standards and other regulations: None
(ii) Changes in accounting policies due to other reasons: None
(iii) Changes in accounting estimates: None
(iv) Restatement: None

(4) Number of issued shares (common shares)

(i) Total number of issued shares at the end of the period (including treasury shares)

As of September 30, 2026	73,025,942 shares
As of March 31, 2026	73,025,942 shares

(ii) Number of treasury shares at the end of the period

As of September 30, 2026	7,660,199 shares
As of March 31, 2026	8,324,319 shares

(iii) Average number of shares outstanding during the period (cumulative from the beginning of the fiscal year)

Six months ended September 30, 2026	65,174,390 shares
Six months ended September 30, 2025	63,002,269 shares

* Semi-annual financial results reports are exempt from review conducted by certified public accountants or an audit firm.

* Proper use of earnings forecasts, and other special matters

Any forward-looking statements contained in this report, including performance projections, are based on information currently available to the Company as well as certain assumptions that the Company determined to be rational at the time of the release of this report, and it is not intended that the Company undertake to achieve such results. Actual results may differ significantly from the projections above, due to a variety of factors.

Please refer to Explanation of Consolidated Financial Forecast for the Fiscal Year Ending March 31, 2027 on page 4 of this report (the attached document) for the suppositions on which the performance projections are based and points that have to be borne in mind for the use of such projections.

○Contents of Attached Document

1. Qualitative Information on Financial Results for the Six Months Ended September 30, 2026 …… 2
(1) Explanation of Management Results …… 2
(2) Explanation of Financial Position …… 4
(3) Explanation of Consolidated Financial Forecast for the Fiscal Year Ending March 31, 2027 …… 4
2. Semi-annual Consolidated Financial Statements and Main Notes …… 5
(1) Semi-annual Consolidated Balance Sheets …… 5
(2) Semi-annual Consolidated Statement of Income and Semi-annual Consolidated Statement of Comprehensive Income …… 7
Semi-annual Consolidated Statement of Income …… 7
Semi-annual Consolidated Statement of Comprehensive Income …… 9
(3) Semi-annual Consolidated Statement of Cash Flows …… 10
(4) Notes Concerning Semi-annual Consolidated Financial Statements …… 12
(Notes Concerning Premise of a Going Business) …… 12
(Notes Concerning Material Changes in Shareholders' Equity) …… 12
(Segmental Information) …… 13

1. Qualitative Information on Financial Results for the Six Months Ended September 30, 2026

(1) Explanation of Management Results

During the six-month period ended September 30, 2026, the prescription pharmaceuticals market saw a 4.02% reduction in NHI drug prices on a drug price basis, following the NHI drug price revisions in April 2026; at the same time, exceptions – such as raising or maintaining the prices of certain drugs in conjunction with the repricing measures of unprofitable products – were also implemented to ensure a stable supply of pharmaceuticals. In addition, based on the revised Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices passed last year, efforts are underway to strengthen the stable supply system for prescription pharmaceuticals and to enhance pharmacy functions, including the partial outsourcing of dispensing operations.

Under these business conditions, the market as a whole exceeded the level of the same period of the previous fiscal year, reflecting the growth of new drugs, centering on specialty pharmaceuticals.

In April of this year, our Group formulated its Medium-term Management Plan 2026-2028, titled “Soaring into the Next Generation,” which covers a three-year period beginning in fiscal year 2026. In this Medium-term Management Plan, we have designated this three-year period as the “Profitability Expansion Phase through Accelerated Growth Investment.” In addition to prescription pharmaceuticals, we are promoting various initiatives across the healthcare sector – including medical devices and materials, reagents, OTC products, and customer support systems – to create new value through proactive alliances and other measures. Our goal is to transform into a “Comprehensive Healthcare Solutions Provider” that delivers this value to our business partners, customers, and patients.

Regarding progress on our Medium-term Management Plan during the interim period, with the goal of achieving the numerical targets for the fiscal year ending March 2029, we have begun reviewing and implementing measures in line with the growth strategies of each business division, company-wide efficiency strategies, and strategies to strengthen our management foundation, and have started monitoring these efforts through the Management Strategy Committee.

・Growth Strategies

With the aim of increasing gross profit in our pharmaceutical wholesaling business, we focused on acquiring specialty pharmaceuticals expected to contribute to profitability and expanding sales of high-growth, high-profit margin products. In addition, we worked to strengthen our sales capabilities by implementing region-specific strategies based on analyses utilizing market data and BI tools, as well as by enhancing the management skills of our responsible personnel. As well as this, we are taking steps to reduce costs by improving logistics efficiency, such as reviewing delivery frequencies based on transaction characteristics and optimizing the outsourcing of delivery operations. Furthermore, to further strengthen our logistics functions and to further enhance and advance the specialty full-line services we already provide, we are proceeding with plans for a comprehensive logistics center in Osaka, which will combine the functions of both manufacturer logistics and wholesale logistics.

Regarding alliances aimed at creating new businesses, we made Ishin Pharma Co., Ltd. a subsidiary in July and launched “Allostem® Sheet,” a regenerative medical product indicated for epidermolysis bullosa. In September, we also signed a memorandum of understanding with Reprocell Inc. regarding the domestic distribution of the regenerative medical product “Stemchymal®.” Furthermore, in October, we invested in AdipoSeeds, Inc., a venture company spun off from Keio University School of Medicine that develops regenerative medical products using platelets.

・Efficiency Strategy

To curb future increases in SG&A expenses, we are promoting initiatives through the two-pronged approach of reducing indirect material costs and reforming business processes. In terms of reducing indirect material costs, we identified products and services that could help reduce costs, and conducted centralized procurement by headquarters as well as reviewing business partners and contracts. In addition, we explored ways to improve productivity in our transportation and delivery operations, and are promoting measures with clearly specified cost savings. Furthermore, with regard to business process reform, looking ahead to future changes in our workforce composition, we are currently implementing specific measures targeting back-office operations, including streamlining through the introduction of DX.

・Strengthening the Management Foundation

As part of our efforts to strengthen our management foundation, we have positioned the promotion of human capital management as a key issue and are working to create a workplace environment where employees can thrive. During this interim period, we have begun reforming our human resources system to strengthen our organizational capabilities and are moving forward with the introduction of a new hierarchy system for management-level personnel. Furthermore, to promote flexible work arrangements, we introduced hourly annual paid leave in April of this year and implemented a fully flexible work system, among other measures designed to support the autonomous growth and increased productivity of our diverse workforce.

The Company’s consolidated operating results for the six months ended September 30, 2026 recorded 808,544 million yen for net sales (an increase of 5.3% year on year), 4,748 million yen for operating profit (a decrease of 34.6% year on year), 6,553 million yen for ordinary profit (a decrease of 21.3% year on year), and 4,177 million yen for profit attributable to owners of parent (a decrease of 33.1% year on year).

The outline of business segment operating results are as follows.

< Pharmaceutical wholesaling business >
While demand for COVID-19-related products decreased significantly, sales of limited-handling products for selected wholesalers, centering on specialty pharmaceuticals, remained solid. With regard to price negotiations with medical institutions, we continue to strive to propose prices commensurate with the value of our products, in accordance with the "Guidelines for the Improvement of Commercial Transaction Practices of Ethical Drugs for Manufacturers, Wholesalers, and Medical Institutions / Pharmacies" established by the Ministry of Health, Labor and Welfare. In addition, following an organizational restructuring implemented this past July, we are working to promote various initiatives, including improving delivery efficiency, by further strengthening coordination between the Sales Division and the Logistics Division.

As for the operating results for the six-month period under review, while sales of limited-handling products for selected wholesalers—including anti-cancer drugs driving the market and specialty pharmaceuticals—expanded steadily, results were affected by rising procurement costs for pharmaceuticals. As a result, the segment recorded 781,345 million yen for net sales (an increase of 5.7% year on year) and 6,357 million yen for segment profit (operating profit) (a decrease of 13.5% year on year).

< Dispensing pharmacy business >
We are moving forward with measures to comply with the dispensing fee revision that took effect on June 1, 2026, and are working to secure technical fees, primarily through the regional healthcare support and pharmaceutical supply system add-on, as well as advancing initiatives in home healthcare, including the assignment of pharmacists specializing in home care. We are also working to build a Customer Data Platform (CDP) to enhance our primary healthcare functions.

As for the operating results for the six-month period under review, while sales increased due to the new consolidation of dispensing pharmacy subsidiaries, they were affected by a decrease in the number of prescriptions filled associated with an increase in long-term prescriptions. As a result, the segment recorded 50,155 million yen for net sales (an increase of 1.2% year on year) and 166 million yen for segment profit (operating profit) (a decrease of 72.3% year on year).

<Pharmaceutical manufacturing and sales business>
With the aim of expanding our CDMO business to accommodate new modalities, we are evaluating multiple contract manufacturing projects and working to establish a system for handling secondary packaging at the Haneda Packaging Center.

As for the operating results for the six-month period under review, affected by delays in launching certain contracted products as well as soaring costs of materials and raw materials, the segment recorded 5,660 million yen for net sales (a decrease of 1.5% year on year) and 109 million yen for segment profit (operating profit) (a decrease of 8.6% year on year).

< Other peripheral businesses >
As for the operating results for the six-month period under review, the segment recorded 3,250 million yen for net sales (a decrease of 9.5% year on year) and 165 million yen for segment profit (operating profit) (a decrease of 65.3% year on year).

(Note) Segment sales include inter-segment transactions.

(2) Explanation of Financial Position

(Assets)

Current assets increased 7.8% from the end of the previous consolidated fiscal year to 615,658 million yen, mainly due to increases in cash and deposits of 8,065 million yen, notes and accounts receivable-trade of 22,313 million yen, and merchandise and finished goods of 11,452 million yen.

Non-current assets increased 0.5% from the end of the previous consolidated fiscal year to 170,580 million yen mainly due to an increase in buildings and structures of 663 million yen.

As a result, consolidated total assets increased 6.1% from the end of the previous consolidated fiscal year to 786,239 million yen.

(Liabilities)

Current liabilities increased 11.4% from the end of the previous consolidated fiscal year to 492,106 million yen, mainly due to an increase in notes and accounts payable-trade of 54,207 million yen.

Non-current liabilities decreased 9.8% from the end of the previous consolidated fiscal year to 24,627 million yen, mainly due to a decrease in bonds payable of 1,753 million yen.

As a result, total liabilities increased 10.1% from the end of the previous consolidated fiscal year to 516,733 million yen.

(Net assets)

Total net assets decreased 0.8% from the end of the previous consolidated fiscal year to 269,505 million yen, mainly due to a decrease in retained earnings of 4,104 million yen, while treasury shares decreased 2,142 million yen.

(Analysis of the Cash Flow Position)

Cash and cash equivalents (hereinafter referred to as “cash”) at the end of the consolidated first half under review increased 10,071 million yen from the end of the previous consolidated fiscal year to 93,357 million yen (an increase of 3,814 million yen year on year).

The status of each cash flow activity and their respective factors during the consolidated first half under review are as follows.

(Cash Flows from Operating Activities)

Net cash provided by operating activities was 20,980 million yen (a decrease of 4,635 million yen year on year). This was mainly due to cash inflow factors such as profit before income taxes of 6,281 million yen, depreciation of 2,923 million yen, and an increase in trade payables of 53,521 million yen, which were offset by cash outflow factors including an increase in trade receivables of 21,807 million yen, an increase in inventories of 11,343 million yen, an increase in other assets of 2,210 million yen, and income taxes paid of 5,885 million yen.

(Cash Flows from Investing Activities)

Net cash used in investing activities was 2,498 million yen (an increase of 501 million yen year on year). This was mainly due to cash inflow factors including proceeds from sales and redemption of securities of 6,000 million yen and proceeds from sales of shares of subsidiaries and associates of 3,600 million yen, which were more than offset by cash outflow factors such as purchase of securities of 4,000 million yen, purchase of property, plant and equipment of 3,222 million yen, and purchase of shares of subsidiaries and associates of 3,806 million yen.

(Cash Flows from Financing Activities)

Net cash used in financing activities was 8,432 million yen (an increase of 4,149 million yen year on year), mainly due to cash outflow factors including dividends paid of 7,765 million yen.

(3) Explanation of Consolidated Financial Forecast for the Fiscal Year Ending March 31, 2027

There are no changes to the consolidated financial forecast for the fiscal year ending March 31, 2027, announced on May 13, 2026.

2. Semi-annual Consolidated Financial Statements and Main Notes
(1) Semi-annual Consolidated Balance Sheet

(Unit: million yen)

	As of March 31, 2026	As of September 30, 2026
Assets		
Current assets		
Cash and deposits	87,361	95,426
Notes and accounts receivable-trade	347,084	369,398
Securities	7,000	7,000
Merchandise and finished goods	89,823	101,275
Raw materials and supplies	152	138
Other	39,911	42,595
Allowance for doubtful accounts	-288	-176
Total current assets	571,044	615,658
Non-current assets		
Property, plant and equipment	89,140	89,175
Intangible assets		
Goodwill	89	117
Other	7,989	8,769
Total intangible assets	8,079	8,887
Investments and other assets		
Other	73,870	73,863
Allowance for doubtful accounts	-1,352	-1,344
Total investments and other assets	72,517	72,518
Total non-current assets	169,737	170,580
Total assets	740,781	786,239

(Unit: million yen)

	As of March 31, 2026	As of September 30, 2026
Liabilities		
Current liabilities		
Notes and accounts payable-trade	414,243	468,450
Short-term borrowings	474	473
Income taxes payable	6,443	3,448
Provision for bonuses	3,795	3,837
Provision for bonuses for directors	49	19
Asset retirement obligations	19	―
Other	16,893	15,876
Total current liabilities	441,920	492,106
Non-current liabilities		
Bonds payable	1,753	―
Long-term borrowings	5,282	5,085
Provision for loss on guarantees	566	―
Retirement benefit liability	2,847	2,953
Asset retirement obligations	3,003	3,049
Other	13,847	13,538
Total non-current liabilities	27,300	24,627
Total liabilities	469,221	516,733
Net assets		
Shareholders' equity		
Share capital	10,649	10,649
Capital surplus	45,212	45,216
Retained earnings	230,378	226,273
Treasury shares	-26,775	-24,632
Total shareholders' equity	259,465	257,507
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	16,417	16,379
Revaluation reserve for land	-4,572	-4,572
Total accumulated other comprehensive income	11,844	11,807
Share acquisition rights	123	122
Non-controlling interests	126	67
Total net assets	271,560	269,505
Total liabilities and net assets	740,781	786,239

(2) Semi-annual Consolidated Statement of Income and Semi-annual Consolidated Statement of Comprehensive Income

Semi-annual Consolidated Statement of Income

(Unit: million yen)

	Six months ended September 30, 2025	Six months ended September 30, 2026
Net sales	767,899	808,544
Cost of sales	708,051	749,324
Gross profit	59,848	59,219
Selling, general and administrative expenses		
Remuneration, salaries and allowances for directors	21,226	21,474
Provision for bonuses	3,653	3,758
Provision for bonuses for directors	26	18
Retirement benefit expenses	247	185
Welfare expenses	4,096	4,140
Vehicle expenses	520	474
Provision of allowance for doubtful accounts	-90	-120
Depreciation	2,673	2,685
Amortization of goodwill	56	37
Rent expenses	4,075	4,207
Taxes and dues	958	1,141
Non-deductible temporary paid consumption tax expense	3,737	3,682
Other	11,409	12,784
Total selling, general and administrative expenses	52,590	54,470
Operating profit	7,258	4,748
Non-operating income		
Interest income	97	116
Dividend income	574	689
Share of profit of entities accounted for using equity method	—	27
Reversal of provision for loss on guarantees	—	566
Other	742	745
Total non-operating income	1,413	2,145
Non-operating expenses		
Interest expenses	27	44
Share of loss of entities accounted for using equity method	5	—
Loss on investments in investment partnerships	65	139
Rental expenses on real estate	87	88
Provision for loss on guarantees	100	—
Other	58	68
Total non-operating expenses	343	340
Ordinary profit	8,329	6,553

(Unit: million yen)

	Six months ended September 30, 2025	Six months ended September 30, 2026
Extraordinary income		
Gain on sale of non-current assets	457	16
Gain on sale of investment securities	53	211
Gain on liquidation of subsidiaries and associates	224	—
Gain on sale of shares of subsidiaries and associates	—	185
Reversal of provision for loss on Antimonopoly Act	371	—
Total extraordinary income	1,105	413
Extraordinary losses		
Loss on disposal of non-current assets	169	55
Loss on extinguishment of tie-in shares	—	573
Other	153	57
Total extraordinary losses	322	686
Profit before income taxes	9,112	6,281
Income taxes-current	2,038	2,862
Income taxes-deferred	822	-758
Total income taxes	2,861	2,103
Profit	6,250	4,177
Profit (loss) attributable to non-controlling interests	5	-0
Profit attributable to owners of parent	6,244	4,177

Semi-annual Consolidated Statement of Comprehensive Income

(Unit: million yen)

	Six months ended September 30, 2025	Six months ended September 30, 2026
Profit	6,250	4,177
Other comprehensive income		
Valuation difference on available-for-sale securities	1,141	-34
Share of other comprehensive income of entities accounted for using equity method	13	-2
Total other comprehensive income	1,155	-37
Comprehensive income	7,405	4,140
Comprehensive income attributable to:		
Comprehensive income attributable to owners of parent	7,400	4,140
Comprehensive income attributable to non-controlling interests	5	-0

(3) Semi-annual Consolidated Statement of Cash Flows

(Unit: million yen)

	Six months ended September 30, 2025	Six months ended September 30, 2026
Cash flows from operating activities		
Profit before income taxes	9,112	6,281
Depreciation	2,899	2,923
Amortization of goodwill	56	37
Increase (decrease) in retirement benefit liability	-54	105
Increase (decrease) in provision for bonuses	24	28
Increase (decrease) in provision for bonuses for directors (and other officers)	-16	-30
Increase (decrease) in allowance for doubtful accounts	-204	-125
Increase (decrease) in provision for loss on guarantees	100	-566
Interest and dividend income	-671	-806
Interest expenses	27	44
Loss (gain) on sale and retirement of non-current assets	-287	38
Loss (gain) on sales and valuation of investment securities	100	-203
Decrease (increase) in trade receivables	-17,166	-21,807
Decrease (increase) in inventories	-761	-11,343
Decrease (increase) in other assets	500	-2,210
Increase (decrease) in trade payables	37,795	53,521
Increase (decrease) in other liabilities	61	847
Increase (decrease) in accrued consumption taxes	428	-1,011
Other loss (gain)	-523	-543
Subtotal	31,420	25,180
Interest and dividends received	638	796
Interest paid	-27	-44
Income taxes paid	-5,363	-5,885
Receipt of returned deposit	2,554	―
Settlement paid	-4,132	―
Other, net	525	933
Net cash provided by (used in) operating activities	25,616	20,980

(Unit: million yen)

	Six months ended September 30, 2025	Six months ended September 30, 2026
Cash flows from investing activities		
Payments into time deposits	-1,970	-1,331
Proceeds from withdrawal of time deposits	3,986	1,337
Purchase of securities	—	-4,000
Proceeds from sale and redemption of securities	—	6,000
Purchase of property, plant and equipment	-3,540	-3,222
Proceeds from sales of property, plant and equipment	840	85
Purchase of intangible assets	-696	-1,332
Proceeds from sale of intangible assets	1	1
Purchase of investment securities	-2,474	-552
Proceeds from sale and redemption of investment securities	284	763
Purchase of shares of subsidiaries and associates	—	-3,806
Proceeds from sale of shares of subsidiaries and associates	—	3,600
Payments for asset retirement obligations	-25	-39
Loan advances	-90	—
Proceeds from collection of loans receivable	70	66
Other, net	614	-68
Net cash provided by (used in) investing activities	-2,999	-2,498
Cash flows from financing activities		
Net increase (decrease) in short-term borrowings	545	220
Repayments of long-term borrowings	-198	-459
Purchase of treasury shares	-6,202	-1
Decrease (increase) in segregated deposits for purchase of treasury shares	-3,844	—
Repayments of finance lease liabilities	-376	-371
Dividends paid	-2,504	-7,765
Purchase of shares of subsidiaries not resulting in change in scope of consolidation	—	-54
Net cash provided by (used in) financing activities	-12,582	-8,432
Net increase (decrease) in cash and cash equivalents	10,034	10,049
Cash and cash equivalents at beginning of period	78,226	83,286
Increase in cash and cash equivalents resulting from merger with unconsolidated subsidiaries	515	21
Increase (decrease) in cash and cash equivalents resulting from change in scope of consolidation	767	—
Cash and cash equivalents at end of period	89,543	93,357

(4) Notes Concerning Semi-annual Consolidated Financial Statements

(Notes Concerning Premise of a Going Business)

Not applicable.

(Notes Concerning Material Changes in Shareholders' Equity)

Not applicable.

(Segmental Information)

I Six months ended September 30, 2025

1. Information about sales and profit or loss by reportable segment

	Reportable segments					Adjustments (million yen) (Note 1)	Amount on semi-annual consolidated statement of income (million yen) (Note2)
	Pharmaceutical Wholesaling (million yen)	Dispensing Pharmacy (million yen)	Pharmaceutical Manufacturing and Sales (million yen)	Other Peripheral Businesses (million yen)	Total (million yen)		
Net Sales							
(1) Sales to external customers	714,217	49,540	1,298	2,843	767,899	—	767,899
(2) Inter-segment sales	24,947	2	4,448	746	30,145	-30,145	—
Total	739,165	49,542	5,747	3,590	798,045	-30,145	767,899
Segment profit	7,349	600	120	475	8,545	-1,287	7,258

（Note） 1. Adjustments for segment profit consist of the elimination of intersegment transactions, the elimination of unrealized profit, and corporate expenses not attributable to any reportable segment.
2. Segment profit is adjusted with operating profit in the interim consolidated statement of income.

2. Information about impairment losses on noncurrent assets or goodwill by each business segment
Not applicable.

II Six months ended September 30, 2026

1. Information about sales and profit or loss by reportable segment

	Reportable segments					Adjustments (million yen) (Note 1)	Amount on semi-annual consolidated statement of income (million yen) (Note2)
	Pharmaceutical Wholesaling (million yen)	Dispensing Pharmacy (million yen)	Pharmaceutical Manufacturing and Sales (million yen)	Other Peripheral Businesses (million yen)	Total (million yen)		
Net Sales							
(1) Sales to external customers	755,426	50,153	473	2,491	808,544	—	808,544
(2) Inter-segment sales	25,919	2	5,186	758	31,865	-31,865	—
Total	781,345	50,155	5,660	3,250	840,410	-31,865	808,544
Segment profit	6,357	166	109	165	6,798	-2,049	4,748

（Note） 1. Adjustments for segment profit consist of the elimination of intersegment transactions, the elimination of unrealized profit, and corporate expenses not attributable to any reportable segment.
2. Segment profit is adjusted with operating profit in the interim consolidated statement of income.

2. Information about impairment losses on noncurrent assets or goodwill by each business segment
Not applicable.